Spero Therapeutics Class Action Lawsuit SPRO | Deadline July 25, 2022
Spero Therapeutics Class Action Lawsuit SPRO

Spero Therapeutics, Inc. (SPRO) is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that:

(i) the data submitted in support of the New Drug Application (“NDA”) for the Company’s product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration (“FDA”); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero’s operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you incurred a loss on SPRO stocks purchased between October 28, 2021 and May 2, 2022, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Eastern District of New York, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until July 25, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Spero Therapeutics, Inc. Class Action Lawsuit
Spero Therapeutics, Inc. Lawsuit
SPRO Class Action Lawsuit
SPRO Lawsuit
Spero Therapeutics, Inc. (SPRO) Class Action Lawsuit